CSA Medical received $23 million in venture debt and equity financing to advance its pair of cryospray therapies.
Here's what you should know:
1. CSA has two cryospray platforms, truFreeze and Rejuvenair. Physicians use the truFreeze spray in Barrett's esophagus and esophageal cancer treatments. Rejuvenair is for chronic obstructive pulmonary disease.
2. Horizon Technology Finance provided the most funding: $15 million in venture loan facility funding and $8 million in equity investment.
3. CSA Medical Executive Chairman Vincent Owens said, "Thanks to the support of our existing investors and new partner Horizon, we will continue to expand the market for truFreeze to treat the full spectrum of esophageal diseases including cancer, and we will continue to advance Rejuvenair to improve quality of life for COPD patients."